Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT) Abstract #1814

Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response
Aim(s): To investigate the clinic-pathological characteristics in patients treated with PRRT
Materials and methods: We performed a retrospective analysis of patients treated from 2011-2016. Patients with at least 1 year of follow-up data from the last treatment were included. Patients with progression within 1 year of finishing treatment (Group 1) were compared to patients with disease stabilisation/response (Group 2). Progression prior to commencement of treatment was defined as either small volume (<20%) or by RECIST
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Georgios Demetriou
Keywords: PRRT, Y90, Lu-177

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1527 Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET).
Introduction: PRRT using Lu-177 is a treatment option for advanced NETs.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Alexander Mc Ewan
#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors
Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Conference: 17th Annual ENETS Conference (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Markus Galler
Authors: Galler M, Schatka I, Buch F, Bluemel S, ...
#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents
Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Franziska Briest
#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETS Conference (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Minseok Suh
Authors: Suh M, Cheon G J, Lee D S, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team